TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Symposium | Customizing first-line BTK inhibitors for CLL: Unmet needs with BTK inhibitors

By Abhilasha Verma

Share:

Featured:

Gilles SallesGilles Salles

Nov 19, 2024

Learning objective: After reading this article, learners will be able to recall the regulatory status of BTK inhibitors and the key treatment guidelines for first-line CLL.


Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.

Question 1 of 2

According to the ESMO guidelines, which of the following treatments is recommended for fit and younger patients with CLL and uIGHV without TP53 mutation or del(17p)?

A

B

C

D

Symposium | Customizing first-line BTK inhibitors for CLL: Unmet needs with BTK inhibitors

During the Lymphoma Hub virtual symposium on October 23, 2024, entitled Customizing first-line Bruton‘s tyrosine kinase (BTK) inhibitors for chronic lymphocytic leukemia (CLL), Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, delivered a presentation on the unmet needs with BTK inhibitors in CLL.

Salles provided an overview of the regulatory status of BTK inhibitors for the first-line treatment of CLL in the US and Europe, touching on the regulatory status of BTK inhibitors as monotherapy and in combination with other therapies, including rituximab, obinutuzumab, bendamustine, and obinutuzumab (Figure 1). Salles also discussed the National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) clinical guidelines for the first-line treatment of CLL (Figure 2).

Figure 1. An overview of the regulatory status of BTK inhibitors for first-line CLL* 

BTK, Bruton’s tyrosine kinase; CLL, chronic lymphocytic leukemia.
*Data from Ibrutinib FDA prescribing information1, Ibrutinib EMA prescribing information2, Acalabrutinib FDA prescribing information3, Acalabrutinib EMA prescribing information4, Zanubrutinib FDA prescribing information5, Zanubrutinib EMA prescribing information6, Pirtobrutinib FDA prescribing information7, ClinicalTrials.gov.8,9
Approved for adult patients with CLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

 

Figure 1. Key guidelines for first-line treatment of CLL*  

CIT, chemoimmunotherapy; CLL, chronic lymphocytic leukemia; del, deletion; ESMO, European Society for Medical Oncology; FCR, fludarabine, cyclophosphamide, rituximab; IGHV, immunoglobulin heavy chain variable; NCCN, National Comprehensive Cancer Network.
*Data from National Comprehensive Cancer Network10 and Eichhorst et al.11
Ibrutinib + venetoclax changed from category 2B to category 2A in the October update.

Watch or download the presentation to learn more about:

  • The regulatory status of BTK inhibitors for first-line CLL, including their approved combinations.
  • The NCCN and ESMO guidelines for first-line CLL, including treatment options for fit or young patients, unfit or older patients, and patients with or without TP53mut or del(17p).

This independent educational activity was supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity.

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content